The bill H. 3096 aims to regulate gene therapy in South Carolina by adding Chapter 141 to Title 44 of the South Carolina Code of Laws. It establishes definitions for terms related to gene therapy, such as "gene therapy product," "genetically modified," and "expose." The bill mandates that any product that could potentially act as a gene therapy or alter genetic material must be labeled as a "Potential Gene Therapy Product," while products confirmed to be gene therapy must be labeled as "Gene Therapy Product." The provisions emphasize the importance of disclosure and require that consumers are made aware of these labels.

Additionally, the bill requires entities that produce or distribute products capable of exposing individuals to genetically modified material to provide information upon written request from residents. This includes details on how individuals may be exposed to such products. Furthermore, the bill stipulates that informed consent must be obtained from individuals who could be exposed to these products, ensuring they are aware of all associated benefits, risks, and potential side effects. The act will take effect upon approval by the Governor.